Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A clinical trial to test whether Azithromycin, a commonly used antibiotic, can treat the symptoms of COVID-19 in outpatients has recruited its first patient.

Azithromycin package © www.doctor-4-u.co.uk/ via Flickr

The ATOMIC2 trial is being led from Oxford with support from the Oxford Clinical Trials Research Unit (OCTRU) at NDORMS. It will enrol 800 people who are being assessed at hospital with COVID-19 but felt well enough to be cared for at home. Half will receive Azithromycin for two weeks, while the rest will get regular care. Participants will also give samples of blood and samples from the nose so researchers can better understand the biology of the virus.

The trial will take place across 15 sites across England, Wales and Scotland. It complements two other national trials – RECOVERY and PRINCIPLE – which are testing Azithromycin in different categories of patients.

The trial's Chief Investigator is Dr Tim Hinks of the University of Oxford's Nuffield Department of Medicine and an Oxford BRC Senior Fellow. He said: "Azithromycin is an antibiotic with unusual anti-inflammatory and anti-viral properties, so it is being seen as a promising potential treatment for COVID-19.

In COVID-19 patients, there is a window of opportunity of about two weeks when the disease progresses from mild symptoms, such as fatigue, fever and cough, to severe respiratory failure.

Azithromycin is safe, inexpensive and available worldwide, so if effective, it could be a very useful weapon in the fight against this pandemic. And even if we find that the drug is not effective against the symptoms of COVID-19, it is still an important finding."

Azithromycin, or AZM, is widely used to tackle a wide range of infections, such as trachoma, a cause of blindness, genital infections, pneumonias, multidrug resistant tuberculosis and a wide range of inflammatory lung diseases and viruses, and so it's important it is only used where really effective to prevent development of antibiotic resistance.
It also has additional antibacterial properties which may help prevent secondary bacterial infection, present in 16 percent of COVID-19 deaths.

The trial has received funding from the NIHR Oxford Biomedical Research Centre (BRC), as well as the University of Oxford and Pfizer.

 

Similar stories

New approach to nail bed injury surgery could significantly cut NHS costs

According to a new Oxford study, changing clinical practice for finger injuries in children could save the NHS £720,000 per year.

Furniss Group paper wins journal award

Editors at the Journal of Hand Surgery have recognised the Furniss Group with an award for the best paper published in the Journal in 2022. The Editor’s Award recognises research with scientific importance, outstanding study stringency, and a high academic standard.

NIHR Fellowships awarded to NDORMS researchers

Congratulations to Eileen Morrow and Mae Chester-Jones who have received NIHR Doctoral Fellowships

ORUK Early Career Research Fellowship awarded to NDORMS researcher

Congratulations to Jack Tu who has been awarded an Orthopaedic Research UK Early Career Research Fellowship to explore the cause of knee pain after total knee replacement.

OCTRU - delivering answers to important clinical questions

The Oxford Clinical Trials Research Unit (OCTRU) has received NIHR benchmarking results and offers excellent value for money according to the report

Unhelpful thoughts about fracture symptoms hinder recovery

The importance of mindsets and feelings about fracture symptoms have been shown to be a key factor in recovery of musculoskeletal conditions.